AI-Powered Precision Learning: Advances in RRMM: Clinical Practice Considerations for Optimizing BCMA Bispecific Antibody Combination Therapy

Relapsed/refractory multiple myeloma (RRMM) remains clinically heterogeneous and increasingly difficult to control across successive lines of therapy, particularly among patients with high-risk disease, extramedullary involvement, or cumulative immune compromise. B-cell maturation antigen (BCMA)-targeted bispecific antibodies have expanded treatment options by providing off-the-shelf T-cell redirection with meaningful activity in heavily pretreated patients, but response depth, durability, tolerability, and feasibility vary by disease biology, prior therapy exposure, tumor burden, and patient-specific factors. Emerging combinations of BCMA bispecific antibodies with CD38-directed antibodies offer a strong mechanistic rationale and encouraging early efficacy, yet clinicians must interpret evolving trial data carefully, relative to bispecific monotherapy, established second-line regimens, and cellular therapies. As these approaches move into earlier lines of therapy and broader practice settings, clinicians need practical strategies for patient selection, sequencing, step-up dosing, toxicity monitoring, and patient-centered care delivery to support safe, individualized integration of bispecific antibody–based regimens in RRMM.

In this CE Concepts AI-powered precision learning activity, expert faculty will examine the biologic rationale, emerging clinical evidence, and practical implementation strategies for BCMA bispecific antibody–CD38 antibody combinations in RRMM, with emphasis on patient selection, sequencing, toxicity management, and integration into evolving earlier-line treatment pathways.

At the conclusion of this activity, learners will be able to better:

• Analyze the mechanistic rationale and immunologic synergy of BCMA bispecific antibody and CD38 antibody combinations to support patient selection and risk stratification in RRMM
• Appraise emerging clinical trial evidence on BCMA bispecific antibody–CD38 antibody combinations, including comparative efficacy and safety versus bispecific monotherapy and other second-line therapies, to inform integration into earlier-line RRMM treatment strategies
• Integrate evidence-based strategies to optimize real-world use of BsAb therapies, with attention to safe dosing, toxicity management, and patient-centered care within evolving standards of practice

Supported by an educational grant from Johnson & Johnson.

Medical oncologists, hematologists/oncologists, oncology nurses, pharmacists, nurse practitioners (NPs), physician associates (PAs), and other health care professionals who treat patients with RRMM

It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Mateos reports the following financial relationships:

Advisory Board: Amgen Inc; Bristol Myers Squibb; GSK; Johnson & Johnson; Kite Pharma/Gilead Sciences; Menarini; Oncopeptides; Pfizer Inc; Regeneron Pharmaceuticals Inc; Sanofi; and Stemline Therapeutics, Inc.

Consultant: Amgen Inc; GSK; Johnson & Johnson; Kite Pharma/Gilead Sciences; and Oncopeptides

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Susan Perry (Planning Committee)
David Modrak, PhD (Planning Committee)
Andrea Perseghin, EdD (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.